Literature DB >> 29752692

Understanding and Therapeutic Strategies of Chinese Medicine on Gut-Derived Uremic Toxins in Chronic Kidney Disease.

Chuan Guo1, Xiang-Rong Rao2.   

Abstract

Chronic kidney disease (CKD) is a major disease that threatens human health. With the progression of CKD, the risk of cardiovascular death increases, which is associated with the elevated levels of uremic toxins (UTs). Representative toxins such as indoxyl sulfate and p-cresyl sulfate are involed in CKD progression and cardiovascular events inseparable from the key role of endothelial dysfunction. The therapeutic strategies of UTs are aimed at signaling pathways that target the levels and damage of toxins in modern medicine. There is a certain relevance between toxins and "turbid toxin" in the theory of Chinese medicine (CM). CM treatments have been demonstrated to reduce the damage of gut-derived toxins to the heart, kidney and blood vessels. Modern medicine still lacks evidence-based therapies, so it is necessary to explore the treatments of CM.

Entities:  

Keywords:  Chinese medicine; chronic kidney disease; therapeutic strategies; uremic toxins

Mesh:

Substances:

Year:  2018        PMID: 29752692     DOI: 10.1007/s11655-017-2926-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  13 in total

1.  Effect of Huanshuai Recipe Oral Liquid ([characters: see text]) on renal dysfunction progression in patients with atherosclerotic renal artery stenosis.

Authors:  Xiu-juan Wang; Xiang-rong Rao; Shen Li; Li Wang; Chang Liu; Gai-hua Zhang; Dong-yan Han; Yu Zhao; Nan-nan Zhang; Xue-xia Li; Shuai Chen
Journal:  Chin J Integr Med       Date:  2015-04-06       Impact factor: 1.978

2.  Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.

Authors:  Masaru Motojima; Atsuko Hosokawa; Hideyuki Yamato; Takamura Muraki; Toshimasa Yoshioka
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.

Authors:  Gerald Schulman; Tomas Berl; Gerald J Beck; Giuseppe Remuzzi; Eberhard Ritz; Kiyoshi Arita; Akira Kato; Miho Shimizu
Journal:  J Am Soc Nephrol       Date:  2014-10-27       Impact factor: 10.121

Review 4.  Chronic Kidney Disease.

Authors:  Angela C Webster; Evi V Nagler; Rachael L Morton; Philip Masson
Journal:  Lancet       Date:  2016-11-23       Impact factor: 79.321

5.  Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD.

Authors:  Hiroshi Shibahara; Nami Shibahara
Journal:  J Nephrol       Date:  2010 Sep-Oct       Impact factor: 3.902

6.  Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease.

Authors:  Stefania Marzocco; Fabrizio Dal Piaz; Lucia Di Micco; Serena Torraca; Maria Luisa Sirico; Domenico Tartaglia; Giuseppina Autore; Biagio Di Iorio
Journal:  Blood Purif       Date:  2013-03-13       Impact factor: 2.614

7.  The uremic retention solute p-cresyl sulfate and markers of endothelial damage.

Authors:  Björn K I Meijers; Soetkin Van Kerckhoven; Kristin Verbeke; Wim Dehaen; Yves Vanrenterghem; Marc F Hoylaerts; Pieter Evenepoel
Journal:  Am J Kidney Dis       Date:  2009-07-17       Impact factor: 8.860

Review 8.  Colon may provide new therapeutic targets for treatment of chronic kidney disease with Chinese medicine.

Authors:  Chuan Zou; Zhao-Yu Lu; Yu-Chi Wu; Li-Hong Yang; Guo-Bin Su; Xi-Na Jie; Xu-Sheng Liu
Journal:  Chin J Integr Med       Date:  2013-01-31       Impact factor: 1.978

9.  Aryl hydrocarbon receptor mediates indoxyl sulfate-induced cellular senescence in human umbilical vein endothelial cells.

Authors:  Masayuki Koizumi; Junko Tatebe; Ippei Watanabe; Junichi Yamazaki; Takanori Ikeda; Toshisuke Morita
Journal:  J Atheroscler Thromb       Date:  2014-04-12       Impact factor: 4.928

10.  Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.

Authors:  Shen Li; Xiang-Rong Rao; Xi-Wen Dai; Kun Pei; Lee Wang; Bao-Min Huo; Xiu-Juan Wang; Ling-Xin Kong; Nan-Nan Zhang; Feng-Mei Lian
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

View more
  2 in total

1.  Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study.

Authors:  Ying Zheng; Nian-Song Wang; Yu-Ning Liu; Li-Qun He; Gui-Hua Jian; Xu-Sheng Liu; Zhao-Hui Ni; Xiao-Hong Cheng; Hong-Li Lin; Wen-Hua Zhou; Ya-Ping Wang; Jing-Ai Fang; Ya-Ni He; Hong-Tao Yang; Li-Juan Zhao; Han-Lu Ding; Li-Hua Wang; Ren-Huan Yu; Wen-Ge Li; Zhi-Ming Ye; Wang Guo; Yong-Li Zhan; Hui-Juan Mao; Zhao Hu; Chen Yao; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Chin J Integr Med       Date:  2018-11-22       Impact factor: 1.978

2.  Nanoparticle-Mediated Delivery of Emodin via Colonic Irrigation Attenuates Renal Injury in 5/6 Nephrectomized Rats.

Authors:  Zhaoyu Lu; Chunlan Ji; Xuewen Luo; Yong Lan; Lijuan Han; Yang Chen; Xusheng Liu; Qinzhan Lin; Fuhua Lu; Xiuqing Wu; Rui Guo; Chuan Zou
Journal:  Front Pharmacol       Date:  2021-01-21       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.